Effects of Risperidone on Cytokine Profile in Drug-Naive First-Episode Psychosis

Effects of Risperidone on Cytokine Profile in Drug-Naive First-Episode Psychosis

Author Noto, Cristiano Autor UNIFESP Google Scholar
Ota, Vanessa Kiyomi Google Scholar
Gouvea, Eduardo S. Google Scholar
Rizzo, Lucas B. Autor UNIFESP Google Scholar
Spindola, Leticia M. N. Autor UNIFESP Google Scholar
Honda, Pedro H. S. Google Scholar
Cordeiro, Quirino Autor UNIFESP Google Scholar
Belangero, Sintia Iole Autor UNIFESP Google Scholar
Bressan, Rodrigo Affonseca Autor UNIFESP Google Scholar
Gadelha, Ary Autor UNIFESP Google Scholar
Maes, Michael Google Scholar
Brietzke, Elisa Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Fac Ciencias Med Santa Casa São Paulo
Deakin Univ
Chulalongkorn Univ
Abstract Background: There is robust evidence that schizophrenia is characterized by immune-inflammatory abnormalities, including variations on cytokine levels. the results of previous studies, however, are heterogeneous due to several confounding factors, such as the effects of antipsychotic drugs. Therefore, research on drug-naive first-episode psychosis (FEP) patients is essential to elucidate the role of immune processes in that disorder.Methods: the aim of this study is to compare cytokine levels (IL-2, IL-10, IL-4, IL-6, IFN-gamma, TNF-alpha, and IL-17) in drug-naive FEP patients both before and after treatment with risperidone for 10 weeks, and to investigate possible associations between cytokine levels and clinical responses to treatment and presence of depressive symptoms. It this study, we included 55 drug-naive FEP patients who had repeated measurements of cytokine levels and 57 healthy controls.Results: We found that FEP patients had significantly higher IL-6, IL-10 and TNF-alpha levels than healthy controls. After risperidone treatment, these three cytokines and additionally IL-4 decreased significantly. No significant difference was found between the post-treatment cytokine levels in FEP patients and in healthy controls, suggesting that these alterations in cytokine profiles are a state marker of FEP. No significant association was found between risperidone-induced changes in cytokines and the clinical response to treatment or the presence of depression. There was a significant inverse association between the risperidone-induced changes in IL-10 and the negative symptoms.Conclusions: in conclusion, our results show a specific cytokine profile in FEP patients (monocytic and regulatory T-cell activation) and suggest immunoregulatory effects of risperidone treatment, characterized by suppressant effects on monocytic, Th2, and T-regulatory functions.
Keywords antipsychotic
cytokines
drug-naive
FEP
immunology
inflammation
risperidone
schizophrenia
Language English
Sponsor Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Fundacao Safra
Fundacao ABADS
Janssen
Eli Lilly
Lundbeck
Novartis
Roche
Date 2015-02-01
Published in International Journal of Neuropsychopharmacology. Oxford: Oxford Univ Press, v. 18, n. 4, 8 p., 2015.
ISSN 1461-1457 (Sherpa/Romeo, impact factor)
Publisher Oxford Univ Press
Extent 8
Origin http://dx.doi.org/10.1093/ijnp/pyu042
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000352536800006
URI http://repositorio.unifesp.br/handle/11600/38654

Show full item record




File

Name: WOS000352536800006.pdf
Size: 626.5Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account